Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.

about

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.

Item

http://www.wikidata.org/entity/Q55339111

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Onset and duration of effect o ...... advanced Parkinson's disease.

@en

Onset and duration of effect o ...... advanced Parkinson's disease.

@nl

type

Item

label

Onset and duration of effect o ...... advanced Parkinson's disease.

@en

Onset and duration of effect o ...... advanced Parkinson's disease.

@nl

altLabel

Onset and duration of effect o ...... nced Parkinson’s disease

@en

prefLabel

Onset and duration of effect o ...... advanced Parkinson's disease.

@en

Onset and duration of effect o ...... advanced Parkinson's disease.

@nl

P1476

Onset and duration of effect o ...... advanced Parkinson's disease.

@en

P2093

Aaron Ellenbogen

http://www.w3.org/2001/XMLSchema#string

Nishit B Modi

http://www.w3.org/2001/XMLSchema#string

Sarita Khanna

http://www.w3.org/2001/XMLSchema#string

Suneel Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease

Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-en

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release

Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.

Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations.

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Determination of minimal clinically important change in early and advanced Parkinson's disease.

The clinically important difference on the unified Parkinson's disease rating scale.

P304

839-845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/NDT.S153321

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Hauser

P577

2018-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29606877

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

levodopa

P932

5868609

http://www.w3.org/2001/XMLSchema#string